TuHURA Biosciences (HURA) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Stablecoin Development (SDEV) over the past year, losing 26.1% versus a loss of 66.8%. Over five years, HURA leads with a -99.9% price change compared with -99.9% for SDEV. TuHURA Biosciences is the larger company by market cap ($123.0 million vs $103.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | SDEV |
|---|---|---|
| Share price | $1.93 | $1.99 |
| Market cap | $122.99M | $102.99M |
| 1-day change | -2.53% | -28.42% |
| YTD return | +154.95% | -92.94% |
| 1-year return | -26.05% | -66.83% |
| 5-year return | -99.87% | -99.94% |
| EPS (TTM) | $-0.54 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.43 | $99.75 |
| 52-week low | $0.41 | $0.78 |
| Distance from 52-week high | -43.73% | -98.01% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +316.58% | — |
| Average volume | 249.19K | 11.42M |
| Shares outstanding | 63.73M | 51.75M |
| Employees | 22 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed SDEV by 40.8 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
HURA vs SDEV FAQ
Which is bigger, TuHURA Biosciences or Stablecoin Development?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $122.99M compared with $102.99M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, HURA or SDEV?
HURA returned -26.05% over the past 12 months, compared with -66.83% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.